Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy

DeAngelo, Daniel J., Sekeres, Mikkael A., Ottmann, Oliver

, Sanz, Miguel A., Naoe, Tomoki, Taube, Tillmann, Belsack, Valerie, Ge, Miaomiao and Doehner, Hartmut 2015. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy. Clinical Lymphoma, Myeloma and Leukemia 15 , S194-S194. 10.1016/j.clml.2015.04.046

Full text not available from this repository.

Official URL: http://dx.doi.org/10.1016/j.clml.2015.04.046

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Elsevier
ISSN:	2152-2650
Last Modified:	02 Nov 2022 09:54
URI:	https://orca.cardiff.ac.uk/id/eprint/96773

Actions (repository staff only)

Edit Item

Altmetric

Dimensions

CORE (COnnecting REpositories)